论文部分内容阅读
目的观察不同剂量的辛伐他汀调脂的临床疗效及安全性。方法分别采用辛伐他汀 5 mg及 2 0 mg治疗高脂血症患者各 5 6例、5 8例 ,观察对比治疗前后血脂各参数变化及副作用。结果治疗后 4周两组血清总胆固醇 (TC)、低密度脂蛋白 (L DL-C)、甘油三酯(TG)均明显降低 (P<0 .0 5 )。 5 mg组血清 TC、L DL-C、TG分别下降 17.8%、2 4.0 %、13.9% ;2 0 mg组血清总胆固醇、L DL-C、甘油三酯分别下降 32 .6 %、36 .2 %、2 8.7% ,组间比较有显著性差异。 5 mg组总胆固醇、LDL -C、甘油三酯达标率分别为 5 1.8%、5 0 .0 %、5 .4% ;2 0 mg组 TC、LDL -C、TG达标率分别为 77.4%、74.1%、17.2 % ,组间比较有显著性差异。辛伐他汀 5 mg组副作用发生率 5 .3% ;2 0 mg组副作用发生率 6 .9% ,两组比较无显著性差异 (P>0 .0 5 )。结论治疗高脂血症 ,预防心血管事件 ,辛伐他汀 2 0 mg更适宜
Objective To observe the clinical efficacy and safety of different doses of simvastatin. Methods Fifty-six and fifty-eight cases of simvastatin 5 mg and 20 mg respectively were treated with hyperlipidemia. The changes of blood lipid parameters and side effects were observed and compared before and after treatment. Results Serum total cholesterol (TC), low density lipoprotein (L-DL-C) and triglyceride (TG) were significantly lower in both groups at 4 weeks after treatment (P <0.05). Serum TC, L DL-C and TG in 5 mg group decreased by 17.8%, 2.04% and 13.9% respectively; serum total cholesterol, L DL-C and triglyceride in 20 mg group decreased by 32.6% and 36.2 %, 2 8.7%, there were significant differences between groups. The compliance rates of total cholesterol, LDL-C and triglyceride in 5 mg group were 51.8%, 50.0% and 5.4% respectively. The compliance rates of TC, LDL-C and TG in 20 mg group were 77.4% 74.1%, 17.2%, there were significant differences between groups. The incidence of side effects in simvastatin 5 mg group was 5.3%, and that in 20 mg group was 6.9%. There was no significant difference between the two groups (P> 0.05). Conclusion Treatment of hyperlipidemia, prevention of cardiovascular events, simvastatin 20 mg is more appropriate